PL2672970T3 - Postacie rifaksyminy i sposoby ich wykorzystania - Google Patents

Postacie rifaksyminy i sposoby ich wykorzystania

Info

Publication number
PL2672970T3
PL2672970T3 PL12745372T PL12745372T PL2672970T3 PL 2672970 T3 PL2672970 T3 PL 2672970T3 PL 12745372 T PL12745372 T PL 12745372T PL 12745372 T PL12745372 T PL 12745372T PL 2672970 T3 PL2672970 T3 PL 2672970T3
Authority
PL
Poland
Prior art keywords
rifaximin
forms
Prior art date
Application number
PL12745372T
Other languages
English (en)
Inventor
Stephan Parent
Lisa McQUEEN
Patricia Andres
Paul Schields
Yiduo Wu
Fei Ding
Jared P. Smit
Original Assignee
Salix Pharmaceuticals, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals, Ltd. filed Critical Salix Pharmaceuticals, Ltd.
Publication of PL2672970T3 publication Critical patent/PL2672970T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL12745372T 2011-02-11 2012-02-10 Postacie rifaksyminy i sposoby ich wykorzystania PL2672970T3 (pl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161441902P 2011-02-11 2011-02-11
US201161530905P 2011-10-18 2011-10-18
US201161556649P 2011-11-07 2011-11-07
US201261583024P 2012-01-04 2012-01-04
EP12745372.8A EP2672970B1 (en) 2011-02-11 2012-02-10 Forms of rifaximin and uses thereof
PCT/US2012/024746 WO2012109605A2 (en) 2011-02-11 2012-02-10 Forms of rifaximin and uses thereof

Publications (1)

Publication Number Publication Date
PL2672970T3 true PL2672970T3 (pl) 2018-11-30

Family

ID=46513026

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12745372T PL2672970T3 (pl) 2011-02-11 2012-02-10 Postacie rifaksyminy i sposoby ich wykorzystania

Country Status (17)

Country Link
US (6) US8735419B2 (pl)
EP (1) EP2672970B1 (pl)
JP (1) JP6076267B2 (pl)
KR (1) KR20140026379A (pl)
CN (1) CN103827122B (pl)
AU (1) AU2012214239B2 (pl)
BR (1) BR112013020265A2 (pl)
CA (1) CA2825964A1 (pl)
EA (1) EA201391171A1 (pl)
ES (1) ES2682965T3 (pl)
IL (1) IL227642A0 (pl)
MX (1) MX350448B (pl)
PH (1) PH12018501404A1 (pl)
PL (1) PL2672970T3 (pl)
PT (1) PT2672970T (pl)
SG (1) SG192122A1 (pl)
WO (1) WO2012109605A2 (pl)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
CN104650114A (zh) 2008-02-25 2015-05-27 萨利克斯药品有限公司 利福昔明的多种形式及其用途
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
JP2014532723A (ja) 2011-11-02 2014-12-08 サリックス ファーマスーティカルズ,リミテッド 過敏性腸症候群(ibs)及び感染症を治療するための方法
US9359374B2 (en) 2012-06-13 2016-06-07 Apotex Pharmachem Inc. Polymorphic forms of rifaximin
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
ES2621557T3 (es) 2014-03-31 2017-07-04 Euticals S.P.A. Mezcla polimórfica de rifaximina y su uso para la preparación de formulaciones sólidas
CA2947962C (en) 2014-05-04 2024-01-16 Salix Pharmaceuticals, Inc. Ibs microbiota and uses thereof
KR102362719B1 (ko) 2014-05-12 2022-02-14 알파시그마 에스.피.에이. 리팍시민의 신규한 용매화 결정 형태, 생산물, 조성물 및 이의 용도
WO2016204474A2 (ko) * 2015-06-18 2016-12-22 주식회사대성미생물연구소 리팍시민 결정체를 포함하는 동물 장염 치료용 수의학적 조성물
US11624125B2 (en) 2018-09-25 2023-04-11 Northwestern University Stabilization of colloidal crystals engineered with nucleic acid

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1199374B (it) 1984-05-15 1988-12-30 Alfa Farmaceutici Spa Processo per la preparazione di pirido-imidazo-rifamicine
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
US7923553B2 (en) * 2003-11-07 2011-04-12 Alfa Wassermann, S.P.A. Processes for the production of polymorphic forms of rifaximin
US8003118B2 (en) 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
CA2663776C (en) 2006-09-22 2016-01-26 Cipla Limited Rifaximin in an amorphous form
US20100136125A1 (en) 2006-12-28 2010-06-03 Jacobus Pharmaceutical Company, Inc. Method of treating inflammatory bowel disease
ITMI20071241A1 (it) 2007-06-20 2008-12-21 Solmag S P A Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta
AU2008273699A1 (en) 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin
US7709634B2 (en) 2007-09-20 2010-05-04 Apotex Pharmachem Inc. Amorphous form of rifaximin and processes for its preparation
JP2011500552A (ja) 2007-10-10 2011-01-06 ルピン・リミテッド 胃腸障害を処置するための医薬用組み合わせおよび組成物
US8486956B2 (en) 2008-02-25 2013-07-16 Salix Pharmaceuticals, Ltd Forms of rifaximin and uses thereof
CN104650114A (zh) 2008-02-25 2015-05-27 萨利克斯药品有限公司 利福昔明的多种形式及其用途
US20100209495A1 (en) 2008-09-17 2010-08-19 Mylan Laboratories, Inc. Granulates, process for preparing them and pharmaceutical products containing them
AU2009326167A1 (en) 2008-12-10 2010-06-17 Cipla Limited Rifaximin complexes
KR20140015140A (ko) 2009-10-27 2014-02-06 루핀 리미티드 리팍시민의 고형 분산물
WO2011153444A1 (en) * 2010-06-03 2011-12-08 Salix Pharmaceuticals, Ltd New forms of rifaximin and uses thereof

Also Published As

Publication number Publication date
US20120207833A1 (en) 2012-08-16
US8735419B2 (en) 2014-05-27
KR20140026379A (ko) 2014-03-05
JP6076267B2 (ja) 2017-02-08
AU2012214239A1 (en) 2013-08-15
ES2682965T3 (es) 2018-09-24
PH12018501404A1 (en) 2019-02-27
US8507517B2 (en) 2013-08-13
US20150118307A1 (en) 2015-04-30
US20120207832A1 (en) 2012-08-16
US20130310409A1 (en) 2013-11-21
CA2825964A1 (en) 2012-08-16
WO2012109605A2 (en) 2012-08-16
JP2014512339A (ja) 2014-05-22
EA201391171A1 (ru) 2014-11-28
CN103827122B (zh) 2016-08-31
AU2012214239B2 (en) 2016-06-30
WO2012109605A8 (en) 2012-11-22
WO2012109605A3 (en) 2014-02-20
US9133217B2 (en) 2015-09-15
EP2672970A4 (en) 2015-12-09
NZ613569A (en) 2015-07-31
SG192122A1 (en) 2013-08-30
US20120264774A1 (en) 2012-10-18
BR112013020265A2 (pt) 2017-07-11
MX2013009110A (es) 2014-02-10
CN103827122A (zh) 2014-05-28
EP2672970A2 (en) 2013-12-18
EP2672970B1 (en) 2018-08-01
PT2672970T (pt) 2018-10-11
US20160031897A1 (en) 2016-02-04
US8227482B1 (en) 2012-07-24
IL227642A0 (en) 2013-09-30
MX350448B (es) 2017-09-07

Similar Documents

Publication Publication Date Title
HUS2100012I1 (hu) 4-Imidazopiridazin-1-il-benzamidok és 4-imidazotriazin-1-il-benzamidok mint BTK-gátlók
HK1179608A1 (zh) 利福昔明的晶型及其用途
ZA201208770B (en) New forms of rifaximin and uses thereof
IL233051B (en) Anti-phf-tau antibodies and uses thereof
EP2756410A4 (en) GEOMIGRATION OF USER STATUS
IL227642A0 (en) Rifaximin formulations and their uses
EP2772483A4 (en) 4-AMINOCARBAZOLE COMPOUND AND USE THEREOF
ZA201401653B (en) Pyrazol-4yl-heterocyclyl-carboxamide compounds and methods of use
IL229844B (en) Anti-psgl-1 antibodies and their use
IL230650A (en) Methylphenidate-drug-mediators and processes for their preparation and use
GB201110783D0 (en) Methods and uses
GB201116774D0 (en) Uses and methods
EP2709999A4 (en) QUINAZOLINE-7-ETHER COMPOUNDS AND METHODS OF USE
EP2716359A4 (en) COMPLEX AND USES THEREOF
GB201111775D0 (en) Compounds and uses thereof
EP2693879A4 (en) MIGRASTATINES AND THEIR USES
GB201108490D0 (en) Methods and uses
GB201112080D0 (en) Prodrugs of opioids and uses thereof
GB201111376D0 (en) Prodrugs of opioids and uses thereof
GB201121726D0 (en) Compounds and uses thereof
GB201121551D0 (en) Compounds and uses thereof
ME03310B (me) 4-IMIDAZOPIRIDAZIN-1-jL-BENZAMIDI I 4-IMIDAZOTRIAZIN-1-IL-BENZAMIDl КАО INHIBITORI втк